diabetestalk.net

Medtronic Cardiovascular Group

Director, Indirect Supply Management Leader, Cardiovascular Group Job

Director, Indirect Supply Management Leader, Cardiovascular Group Job

As the Indirect Supply Management (ISM) leader for CVG (Cardiovascular Group), you will be responsible for managing and influencing ~$1B in addressable annual spend across multiple categories, including but not limited to Facilities, Contingent Labor, MRO, Equipment, Marketing, IT, Professional Services, Legal, HR, Travel. You will partner with the center-led supply management teams and multiple site-level stakeholders to leverage and implement pan-Medtronic procurement strategies within the CVG BUs and at each of their manufacturing sites. Through strategic leadership, you will work to optimize indirect services in terms of quality, response time, and total cost of ownership. Candidates who currently live or are open to relocation to Minneapolis, MN are strongly preferred. However, we may consider candidates based in the additional locations on this job posting. The ISM Director will have overall responsibility for leading a team of resources in the development and implementation of strategies and goals for the CVG business group, in support of their business objectives for cycle/response time, quality assurance, and total cost. Key job duties/responsibilities are listed below: Lead a team of 3 direct reports in managing and influencing ~$1B in annual spend across multiple categories: Facilities, Contingent Labor, MRO, Equipment, Marketing, IT, Professional Services, Legal, HR, Travel, amongst others Partner closely with center-led supply management organization to understand and implement key pan-Medtronic strategies Share business group and site-specific requirements and concerns with the center-led supply management organization Partner closely with key business group functions that support supply management e.g., finance, quality Provide updates to VP, Sourcing fo Continue reading >>

Medtronic To Present New Clinical Data On Vascular Interventions And Key Symposia At Veithsymposium 2017

Medtronic To Present New Clinical Data On Vascular Interventions And Key Symposia At Veithsymposium 2017

1:00 p.m. - AIM Symposium: Treatment of Pelvic Reflux and Prostate Artery Embolization 6:57 a.m. - DEBATE:Not So: With Modern Endografts and Improved Techniques EVAR Outside IFUs Can Have Good Outcomes with Low Rates of Endoleaks and Sac Growth Session 9: Grand Ballroom East, Third Floor 11:39 a.m. - For Short Necked AAAs Standard EVAR Plus Fixing with EndoAnchors is the Best Treatment for Many Patients; What Are the Limits? Session 12: Grand Ballroom West, Third Floor 12:00 p.m. - Symposium: Treating Simple to Complex Femoropopliteal Lesions Through Luminal Gain and Drug-Coated Balloon Technology Location: Medtronic Pavilion, Third Floor Speakers: Gunnar Tepe, M.D., William Gray, M.D., Eric Scott, M.D. 10:45 a.m. - Early Clinical Results and Experience with Next Generation Valiant Navion Low-Profile TEVAR Device Session 57: Grand Ballroom West, Third Floor 12:00 p.m. - Symposium: Expanding Patient Care Options Location: Medtronic Pavilion, Third Floor Speakers: David Deaton, M.D., William Jordan, M.D., Frank R. Arko III, M.D. 12:00 p.m. - Symposium: VenaSeal Closure System Panel Discussion: The Procedure, The Patients and Your Practice Speakers: Kathleen Gibson, M.D., Joseph Ricotta, M.D., Manjit Gohel, M.D. 3:25 - 4:12 p.m. - Concurrent EndoAnchor Sessions: Indication and Value, EndoAnchors with TEVAR Session 61: Grand Ballroom West, Third Floor Moderators: Luis Sanchez, M.D., William Jordan, M.D. In collaboration with leading clinicians, researchers, and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services of the highest quality that deliver clinical and economic value to healthcare Continue reading >>

Sales Representative Cardiac And Vascular Group

Sales Representative Cardiac And Vascular Group

Together, we can change healthcare worldwide. At Medtronic, we push the limits of what technology can do to help alleviate pain, restore health and extend life. We challenge ourselves and each other to make tomorrow better than yesterday. It is what makes this an exciting and rewarding place to be. We can accelerate and advance our ability to create meaningful innovations - but we will only succeed with the right people on our team. Let's work together to address universal healthcare needs and improve patients' lives. Help us shape the future. At Medtronic we are always looking to speak to great talent. With presence across Vietnam, we have vacancies for Sales Representatives and Marketing Specialists across our Cardio and Vascular Group in Kuala Lumpur, George Town and Johor Bahru. This includes Coronary, Cardiac Rhythm and Heart Failure Management and Structural Heart Sales Representatives, CRHF Clinical Specialists and Structural Heart Senior Marketing Specialists. Sales Representatives play a very important part in Medtronic's success. They educate customers, promote our brand and act as trusted partners to our clients through the sale of product portfolios within a defined region. They have the support of a great team of Clinical Specialists, Sales Managers and Marketing Executives to help build the Medtronic brand too. Where do you fit in? Click here at for some more information about our Cardiac and Vascular Group. You will have demonstrated experience in Medical Device Sales. Knowledge and or working experience in the Cardiovascular industry will be highly regarded. We will also consider highly motivated/customer facing individuals with Cardiovascular pharmaceutical sales experience who are looking to make a move into Devices. Ideally you will be a relationship Continue reading >>

Medtronic

Medtronic

Medtronic Public Limited Company is a medical device company. Its headquarters are in Dublin, Ireland.[1][3][4][5] Its operational headquarters are in Fridley, Minnesota.[1][6] Medtronic is among the world's largest medical equipment development companies.[7] In 2015, at the time of its acquisition of Covidien, its market capitalisation was about $100 billion.[8] Medtronic operates in more than 140 countries.[1] It employs over 85,000 people and has more than 53,000 patents.[9] History[edit] Early history[edit] Medtronic Operational Headquarters in Fridley, Minnesota, a suburb of Minneapolis. Medtronic was founded in 1949 in northeastern Minneapolis by Earl Bakken and his brother-in-law, Palmer Hermundslie, as a medical equipment repair shop.[10] Through his repair business, Bakken came to know C. Walton Lillehei, a doctor of heart surgery at the University of Minnesota Medical School. The deficiencies of the pacemakers of the day were made painfully obvious following a power outage over Halloween in 1957, which affected large sections of Minnesota and western Wisconsin.[11] A pacemaker-dependent paediatric patient of Lillehei died because of the blackout. The next day, Lillehei spoke with Bakken about developing some form of battery-powered pacemaker. Bakken modified a design for a transistorised metronome and created the first battery-powered external artificial pacemaker. Medtronic's old headquarters in St. Anthony, Minnesota The company expanded through the 1950s, mostly selling equipment built by other companies but also developing some custom-made devices. Bakken built a small pacemaker that could be strapped to the body and powered by batteries. Work in the new field later produced an implantable pacemaker in 1960. The company built headquarters in the Minneapoli Continue reading >>

About Medtronic Ecr Journal

About Medtronic Ecr Journal

European Cardiovascular Disease 2006 - Issue 1;2006:2(1):1-1 Medtronic is the global leader in medical technology - alleviating pain, restoring health, and extending life for millions of people worldwide. With deep roots in the treatment of heart disease, Medtronic now provides a wide range of products and therapies - every six seconds, somewhere in the world, a persons life is saved or improved by a Medtronic product or therapy. Medtronic was founded on 29 April 1949 in Minneapolis, Minnesota, US, by Earl E Bakken and Palmer J Hermundslie. Medtronic Cardiac Rhythm Management (CRM) develops products that restore and regulate a patients heart rhythm, as well as improve the hearts pumping function. The business markets implantable pacemakers, defibrillators, cardiac ablation catheters, monitoring and diagnostic devices and cardiac resynchronisation devices, including the first implantable device for the treatment of heart failure. In addition, the business markets automated external defibrillators (AEDs) - which are increasingly being placed in public places, such as businesses, airports, shopping centres and even homes - and the CareLink Patient Network, the industrys first Internet-based network to enable physicians to remotely monitor their patients who have cardiac devices. Medtronic Cardiac Surgery develops products that are used in both arrested and beating heart bypass surgery. The business also markets the industrys broadest line of heart valve products for replacement and repair, plus autotransfusion equipment and disposable devices for handling and monitoring blood during major surgery, as well as cardiac ablation devices to treat a variety of heart conditions. Medtronic Vascular offers products and therapies that treat a wide range of vascular diseases and con Continue reading >>

Press Release | Newsroom | Medtronic | Medtronic To Form A Single, Unified U.s. Cardiac And Vascular Group Sales Organization

Press Release | Newsroom | Medtronic | Medtronic To Form A Single, Unified U.s. Cardiac And Vascular Group Sales Organization

Medtronic to Form a Single, Unified U.S. Cardiac and Vascular Group Sales Organization New Structure Uniquely Positions Medtronic to Maintain Focus on Clinicians While Addressing the Needs of Cardiac and Vascular-focused Hospital Administrators MINNEAPOLIS April 7, 2011 Responding to the challenges hospitals face in the changing healthcare environment, as well as the increasing importance of the hospital administrator as a decision maker in device selection, Medtronic, Inc. (NYSE: MDT) today announced it will combine its U.S. Cardiac and Vascular Group sales functions into a single, unified cross-divisional sales organization effective at the start of Medtronics new fiscal year, May 1, 2011. David Roberts, formerly vice president of sales for the Cardiac Rhythm Disease Management business at Medtronic, assumes the leadership of this new 2,700 person organization as the national vice president, Cardiac and Vascular Group Sales. Unique in the medical device industry, the Cardiac and Vascular Group of businesses at Medtronic operate across 15 cardiovascular market segments and maintain leading market share positions in nearly all of them. The Cardiac and Vascular Group of businesses at Medtronic have nearly three times the depth and breadth of its nearest competitors. Cardiac and vascular-focused hospital administrators are typically responsible for making device selections across the full cardiovascular spectrum. "Our Cardiac and Vascular Group of businesses have historically focused primarily on clinicians as the primary decision makers for medical device selection for their patients," said Michael Coyle, executive vice president and group president of the Cardiac and Vascular Group of businesses at Medtronic. "With the growing partnership between clinicians and adminis Continue reading >>

Medtronic Vascular, Inc. Key Developments

Medtronic Vascular, Inc. Key Developments

Medtronic Vascular, Inc. designs and manufactures technologies for coronary, peripheral, and neurovascular indications. The companys products include S7 Zipper MX Coronary Stent System, Clo-Sur PAD nonwoven Hydrophilic wound dressing, Launcher Coronary Guide Catheter, and Stormer Over-the-Wire Balloon Dilatation Catheter. The company also offers Bridge Assurant balloon-expandable stent delivery system, GuardWire Plus Temporary Occlusion and Aspiration System, and S660 Coronary Stent. The company was formerly known as Medtronic AVE, Inc. and changed its name to Medtronic Vascular, Inc. in October 2003. The company was incorporated in 1991 and is based in Santa Rosa, California. As of January... Medtronic Vascular, Inc. designs and manufactures technologies for coronary, peripheral, and neurovascular indications. The companys products include S7 Zipper MX Coronary Stent System, Clo-Sur PAD nonwoven Hydrophilic wound dressing, Launcher Coronary Guide Catheter, and Stormer Over-the-Wire Balloon Dilatation Catheter. The company also offers Bridge Assurant balloon-expandable stent delivery system, GuardWire Plus Temporary Occlusion and Aspiration System, and S660 Coronary Stent. The company was formerly known as Medtronic AVE, Inc. and changed its name to Medtronic Vascular, Inc. in October 2003. The company was incorporated in 1991 and is based in Santa Rosa, California. As of January 29, 1999, Medtronic Vascular, Inc. operates as a subsidiary of Medtronic plc. Continue reading >>

Mardil | Board Of Directors

Mardil | Board Of Directors

Jim Buck joined Mardil Medical in September, 2010 after more than nineteen years of experience successfully developing and commercializing innovative medical technologies. Prior to joining Mardil, Jim served as President & CEO of SetPoint Medical, a privately funded early stage developer of an implantable neuromodulation device system to regulate uncontrolled inflammation; VP, marketing & business development at InnerPulse, a privately funded developer of a novel implantable defibrillator system; and VP, marketing & business development at Closure Medical, leading the product mapping strategy and execution for a breakthrough surgical sealant and adhesive technology culminating in a $370 million acquisition and integration into Johnson & Johnson. Previous to Closure Medical/J&J, Jim held several positions of increasingly greater responsibility over eleven years at cardiac medical device leader St. Jude Medical. Jim holds a master of management from Northwestern Universitys Kellogg Graduate School of management and a bachelors degree from Indiana University. Jim resides with his wife Lisa and four children in Orono, MN. Dr. Stanton joined Mardils Board in 2012 and is Vice President and General Manager of the Implantable Defibrillator business within Medtronics Cardiac Rhythm Disease Management (CRDM) business. Marshall has over 25 years of experience in cardiac rhythm management including 15 years at Medtronic and 10 years as a staff cardiologist at Mayo Clinic. Prior to his current role, Dr. Stanton was Vice President for Clinical Research for Medtronics Cardiac and Vascular Group of businesses. Recently, Dr. Stanton was Vice President and General Manager for the Medtronic Japan CRDM business from May 2005 through June 2007 where he had responsibility for all aspects of Continue reading >>

Cardiac And Vascular Group - Case Studies | Medtronic

Cardiac And Vascular Group - Case Studies | Medtronic

CASE STUDIES CARDIAC AND VASCULAR SOLUTIONS PRO|CVSM helped this heart and vascular healthcare system achieve cross-functional process improvements which resulted in more patient time spent face-to-face with their clinician, as compared to their total time spent at the clinic. This leading cardiovascular care center partnered with PRO|CV to proactively examine every aspect of their TAVR operation. By streamlining workflow procedures, they saw significant improvements in patient wait times, staff efficiency, and clinical processes and protocols. MEETING THE DEMAND FOR REMOTE DEVICE MONITORING PRO|CV partnered with this midwestern heart center to standardize and streamline remote management procedures. The result was an increase in remote patient transmissions viewed each day without increasing staff. REDUCING 30-DAY HEART FAILURE READMISSIONS At the end of 2013, this medical center was seeing higher than desired 30-day heart failure readmissions. In partnership with Medtronic Connect HFSM they established a more efficient process for managing heart failure patients, and brought their 30-day readmission percentage below the national average. Continue reading >>

Business Unit Descriptions

Business Unit Descriptions

Business Unit Information for Grants and Donations Please use the descriptions below to help determine which business unit should be selected on the request form. In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic CVG offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. AORTIC:Abdominal and thoracic aortic disease treated with a stent graft. CARDIAC RHYTHM AND HEART FAILURE (CRHF):Devices and therapies to treat abnormal heart rhythms, as well as cardiac diagnostic and monitoring solutions. MECHANICAL CIRCULATORY SUPPORT (MCS) formerly HeartWare:Partnering with clinicians, researchers and scientist worldwide to advance Ventricular Assist Device therapy for the treatment of end stage heart failure. CORONARY:Interventional devices to treat coronary arteries that are blocked by atherosclerotic plaque to restore blood flow to the heart. ENDOVENOUS:Diagnostic and catheter based technologies utilized to treat chronic venous insufficiency (CVI). PERIPHERAL:Interventional devices used to treat peripheral artery disease (PAD) through catheter-based procedures and diagnostic technologies. RENAL DENERVATION (RDN):Devices to ablate the renal nerves for the treatment of hypertension and other diseases associated with excess renal sympathetic drive. STRUCTURAL HEART: Devices and therapies to treat structural defects of the heart including cannulae, beating heart products, blood management, perfusion products, surgical ablation, surgical valves and rings, and transcatheter valves. Minimally Invasive Therapies Group (MITG) Formerly Covidien We aspire to enable earlier diagnosis, better treatment, faster complication-free recovery, and enhanced pa Continue reading >>

Director, Indirect Supply Management Leader, Cardiovascular Group

Director, Indirect Supply Management Leader, Cardiovascular Group

Director, Indirect Supply Management Leader, Cardiovascular Group 11 - 15 years experience Manufacturing As the Indirect Supply Management (ISM) leader for CVG (Cardiovascular Group), you will be responsible for managing and influencing ~$1B in addressable annual spend across multiple categories, including but not limited to Facilities, Contingent Labor, MRO, Equipment, Marketing, IT, Professional Services, Legal, HR, Travel. You will partner with the center-led supply management teams and multiple site-level stakeholders to leverage and implement pan-Medtronic procurement strategies within the CVG BUs and at each of their manufacturing sites. Through strategic leadership, you will work to optimize indirect services in terms of quality, response time, and total cost of ownership. Candidates who currently live or are open to relocation to Minneapolis, MN are strongly preferred. However, we may consider candidates based in the additional locations on this job posting. A DAY IN THE LIFE:The ISM Director will have overall responsibility for leading a team of resources in the development and implementation of strategies and goals for the CVG business group, in support of their business objectives for cycle/response time, quality assurance, and total cost. Key job duties/responsibilities are listed below: Lead a team of 3 direct reports in managing and influencing ~$1B in annual spend across multiple categories: Facilities, Contingent Labor, MRO, Equipment, Marketing, IT, Professional Services, Legal, HR, Travel, amongst others Partner closely with center-led supply management organization to understand and implement key pan-Medtronic strategies Share business group and site-specific requirements and concerns with the center-led supply management organization Partner closely Continue reading >>

Medtronic Is Facing Growing Challenges From Boston Scientific And Abbott Laboratories | Stock News & Stock Market Analysis - Ibd

Medtronic Is Facing Growing Challenges From Boston Scientific And Abbott Laboratories | Stock News & Stock Market Analysis - Ibd

Medtronic ( MDT ) will overcome Hurricane Maria's impact in fiscal 2018, but the maker of medical devices is expected to face growing competition from Abbott Laboratories ( ABT ) and Boston Scientific ( BSX ) in heart implants, an analyst said Thursday. XIn September, Abbott caught up to Medtronic and Boston, gaining approval for an implantable cardioverter defibrillator, or ICD, that allows a patient to undergo an MRI scan if needed. These devices are implanted to help control abnormal heart rhythm . Still, RBC analyst Glenn Novarro says the lower end of Medtronic's full-year forecast in August for 4%-5% sales growth on a constant basis remains realistic. He increased his view for fiscal 2018 to $29.55 billion in sales and adjusted income of $4.74 per share. "The impact of MR-compliant ICDs from Abbott and Boston is another topic of interest as it relates to the second half of fiscal 2018 and fiscal 2019," he said. For Medtronic's fiscal 2019, Novarro forecasts the firm as managing 3% constant-currency growth. Competitive concerns also extend to heart-valve replacements, Novarro said. In early 2018, he sees Boston re-entering the European market with its Lotus Edge product. Boston recalled the device, not approved in the U.S., due to problems with its locking mechanism. IBD'S TAKE:Medtronic has an IBD Composite Rating of 57, meaning it performs in the top half of all stocks in terms of key growth metrics. But it still falls to No. 54 in the Medical-Products industry group in terms of rankings. Head to IBD Stock Checkup for a look at better-rated medtech players. Despite the mounting competition for its cardiac and vascular group, Novarro sees Medtronic as capable of pulling off its full-year guidance. "We expect management to reaffirm guidance for constant-currency re Continue reading >>

Cardiac And Vascular Group - Connect Hf | Medtronic

Cardiac And Vascular Group - Connect Hf | Medtronic

CONNECT HF Solution CARDIAC AND VASCULAR SOLUTIONS The Connect HFSM solution provides a multi-faceted approach to help healthcare systems bolster the performance of their heart failure programs, from improving patient outcomes to increasing operational efficiencies and expanding access to care. Our nationally recognized clinical advisors have established well-respected heart failure programs that have driven significant improvements in care, including: Connect HF allows you to leverage their experience, as well as resources from Medtronic, to enhance and elevate your heart failure program. With our expertise in Lean Sigma, facilitation, measurement, and change management, Medtronic has led more than 100 successful hospital process improvement engagements, empowering change and enabling healthcare systems to: Improve patient experience and access to care Our team works with you to identify, prioritize, and optimize areas for improvement that align with your clinical goals and program direction. Depending on your needs, the team may also provide on-site support and guidance in the implementation and monitoring of improvements. Following an implementation of the Connect HF Solution, McLaren Regional Medical Center realized a 39.9% relative rate reduction in HF readmissions.1 It hasnt been just the reduction in readmissions, but also the improvement in working together as a care team to improve our critical metrics related to heart failure. James Chambers, DO Chief of Cardiology McLaren Regional Medical Center Continue reading >>

Cardiac And Vascular Group - Pro|cv | Medtronic

Cardiac And Vascular Group - Pro|cv | Medtronic

PRO|CV SOLUTION CARDIAC AND VASCULAR SOLUTIONS PROCESS REDESIGN AND OPTIMIZATION FOR CARDIOVASCULAR SERVICES The PRO|CVSM solution combines proven methodologies with extensive change management expertise to help customers address their unique challenges. Our team has led more than 100 successful hospital and clinic engagements in a wide range of cardiovascular settings, including cardiac cath and EP labs, hybrid ORs, and outpatient clinics. PRO|CV engagements are customized to meet your specific goals. Our analytical approach and extensive cardiovascular experience can help you optimize patient care, improve healthcare efficiency, and ensure sustainable success. A leading heart and vascular clinic in the SoutheastUnited States achieved the following: Increased clinical face time ratio from 44 percent to 67 percent Decreased total time spent in clinic by 18 percent A midwest hospital conducting approximately 520 device implants per year achieved the following: Decreased in-office lead time by 93 percent Potential revenue impact of $143,700 annually A multi-center Catholic health system in the NortheasternUnited States achieved the following: Readmission rate reduced from 32 percent to less than 20 percent The Medtronic PRO|CV engagement improved synergy across the care continuum and helped prepare our system for the emerging risk market, from future bundled payments to innovative risk-sharing models. Reginald Blaber, M.D. Executive Director, Lourdes Cardiovascular Institute Tertiary teaching facility in the midwest that includes a heart and vascular center with five cath labs achieved the following: Decreased cath lab lead time (all cases) by 20 percent Decreased registration lead time by 32 percent A leading cardiovascular care center in the EasternUnited States achiev Continue reading >>

Medtronic To Acquire Ventricular Assist Devicemaker

Medtronic To Acquire Ventricular Assist Devicemaker

Medtronic has announced it will acquire a Framingham, Mass.-based manufacturer specializing in less-invasive devices used to treat heart failure. The Dublin-based devicemaker said it will buy publicly traded HeartWare International for $58 per share, or roughly $1.1 billion in cash. The deal is expected to close during Medtronic's second quarter ending Oct. 28. HeartWare makes the HVAD System, a miniaturized pump that supports circulation of blood through the heart for patients with congestive heart failure, a condition in which the heart isn't pumping enough blood. The device is designed to be implanted less-invasively than comparable devices, in a three-step procedure. The ventricular assist device will allow Medtronic to expand its heart failure business and offer devices that serve patients who have a wider range of needs, said Mike Coyle, executive vice president at Medtronic and president of its cardiac and vascular group. Medtronic already offers several pacemakers. Medtronic estimates the value of the ventricular assist device market at $800 million, while heart failure affects 5.7 million adults in the U.S., according to the Centers for Disease Control and Prevention. Medtronic believes that number will exceed 8 million by 2030, and points out that the U.S. already spends $39 billion a year on heart failure treatment, one of the largest expenses in the healthcare system. HeartWare CEO Doug Godshall expressed optimism that an acquisition by Medtronic will allow the company to more quickly develop and introduce other devices. "Combining the unique capabilities of the HeartWare team, which has been entirely focused on mechanical support technologies, with the broad strength of the Medtronic organization provides a unique opportunity to enhance growth in the mecha Continue reading >>

More in diabetes